CRPC: Cabazitaxel extends radiographic PFS, regardless of age

Key clinical point: Cabazitaxel improves radiographic progression-free survival (rPFS) in older (age, 70 years and above) and younger (age, less than 70 years) patients with metastatic castration-resistant prostate cancer (CRPC) vs abiraterone or enzalutamide.

Major finding: The median rPFS significantly improved with cabazitaxel vs abiraterone/enzalutamide in older (hazard ratio [HR], 0.58; P = .012) and younger patients (HR, 0.47; P < .001). There was no significant improvement in overall survival with cabazitaxel in older (P = .084) and younger patients (P = .093).

Study details: An open-label, randomized CARD study of 255 patients with metastatic CRPC randomly assigned to either cabazitaxel plus prednisone and granulocyte colony-stimulating factor or enzalutamide/abiraterone+prednisone.

,

Disclosures: The study was funded by Sanofi. The authors reported grants or funding, honoraria, consulting/advisory fees, royalties, patents, employment/affiliation, and/or stock ownership/options.

Source: Sternberg CN et al. Eur Urol. 2021 Jul 14. doi: 10.1016/j.eururo.2021.06.021.